Literature DB >> 14586141

Neurological toxicity of ifosfamide.

P Nicolao1, B Giometto.   

Abstract

Ifosfamide is an alkylating agent with well-demonstrated efficacy against a large number of malignant diseases. With cyclophosphamide it shares a toxicity profile characterized by myelosuppression and urotoxicity, but ifosfamide has additionally disclosed adverse neurological effects. Ifosfamide-related central nervous system toxicity is characterized by metabolic encephalopathy of varying severity. Symptoms have been reported in 5-30% of all patients treated with ifosfamide. The mechanism of ifosfamide-related central nervous system toxicity has not been fully elucidated, although the symptoms have most often been noted when the drug is given at high doses or administered orally. The neurotoxicity is generally self-limiting and reversible between 48 and 72 h after discontinuation of ifosfamide, although fatal sequelae have been reported. Therapeutic options are now available. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14586141     DOI: 10.1159/000073352

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  13 in total

Review 1.  Neurologic toxicities of cancer therapies.

Authors:  Robert Cavaliere; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Mesna or cysteine prevents chloroacetaldehyde-induced cell death of human proximal tubule cells.

Authors:  Gerald Schwerdt; Antje Kirchhoff; Ruth Freudinger; Brigitte Wollny; Andreas Benesic; Michael Gekle
Journal:  Pediatr Nephrol       Date:  2007-02-02       Impact factor: 3.714

Review 3.  Pharmacokinetic considerations in the treatment of CNS tumours.

Authors:  Susannah Motl; Yanli Zhuang; Christopher M Waters; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  A database of pediatric drug effects to evaluate ontogenic mechanisms from child growth and development.

Authors:  Nicholas P Giangreco; Nicholas P Tatonetti
Journal:  Med (N Y)       Date:  2022-06-24

5.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

Review 6.  Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.

Authors:  Karen I Sweiss; Rakesh Beri; Stacy S Shord
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 7.  Neurotoxicity of chemotherapeutic and biologic agents in children with cancer.

Authors:  Kevin C De Braganca; Roger J Packer
Journal:  Curr Neurol Neurosci Rep       Date:  2008-03       Impact factor: 5.081

Review 8.  Neoadjuvant Treatment Options in Soft Tissue Sarcomas.

Authors:  Mateusz Jacek Spałek; Katarzyna Kozak; Anna Małgorzata Czarnecka; Ewa Bartnik; Aneta Borkowska; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2020-07-26       Impact factor: 6.639

9.  Oculomotor Deficits after Chemotherapy in Childhood.

Authors:  Einar-Jón Einarsson; Mitesh Patel; Hannes Petersen; Thomas Wiebe; Måns Magnusson; Christian Moëll; Per-Anders Fransson
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

Review 10.  Managing sarcoma: where have we come from and where are we going?

Authors:  Jenna S Bleloch; Reyna D Ballim; Serah Kimani; Jeannette Parkes; Eugenio Panieri; Tarryn Willmer; Sharon Prince
Journal:  Ther Adv Med Oncol       Date:  2017-09-20       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.